MRNA Revenue
Quarterly revenue, the top-line sales a company books before any costs are subtracted.
Revenue
Latest: $145M (2026Q2)
| Period | Value |
|---|---|
| 2023Q1 | $1.86B |
| 2023Q2 | $344M |
| 2023Q3 | $1.83B |
| 2023Q4 | $2.81B |
| 2024Q1 | $167M |
| 2024Q2 | $241M |
| 2024Q3 | $1.86B |
| 2024Q4 | $966M |
| 2025Q1 | $108M |
| 2025Q2 | $142M |
| 2025Q3 | $1.02B |
| 2025Q4 | $678M |
| 2026Q1 | $389M |
| 2026Q2 | $145M |
Other MRNA Charts
More quarter-by-quarter fundamentals for Moderna, Inc.
1 / 10
EPS
Free Cash Flow
Gross Margin
FCF Margin
P/E Ratio
Cumulative FCF
Shares Outstanding
Total Assets
Total Debt
Rule of 40
Healthcare Comparison
1 / 3
Latest Revenue: $145M (2026Q2); +2.1% YoY; −54.4% CAGR (3.25y).
Across the 14 quarters from 2023Q1 to 2026Q2, Revenue ranged from $108M in 2025Q1 to $2.81B in 2023Q4.